[go: up one dir, main page]

CL2008003582A1 - Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash). - Google Patents

Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).

Info

Publication number
CL2008003582A1
CL2008003582A1 CL2008003582A CL2008003582A CL2008003582A1 CL 2008003582 A1 CL2008003582 A1 CL 2008003582A1 CL 2008003582 A CL2008003582 A CL 2008003582A CL 2008003582 A CL2008003582 A CL 2008003582A CL 2008003582 A1 CL2008003582 A1 CL 2008003582A1
Authority
CL
Chile
Prior art keywords
nafld
cystamine
nash
alcoholic
preparation
Prior art date
Application number
CL2008003582A
Other languages
English (en)
Inventor
Ranjan Dohil
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003582(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of CL2008003582A1 publication Critical patent/CL2008003582A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de un producto de cisteamina para preparar un medicamento para tratar hígado graso.
CL2008003582A 2007-11-30 2008-12-01 Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash). CL2008003582A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99151707P 2007-11-30 2007-11-30
US8539708P 2008-07-31 2008-07-31

Publications (1)

Publication Number Publication Date
CL2008003582A1 true CL2008003582A1 (es) 2009-04-03

Family

ID=40679016

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003582A CL2008003582A1 (es) 2007-11-30 2008-12-01 Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).

Country Status (25)

Country Link
US (5) US7994226B2 (es)
EP (2) EP2636404B1 (es)
JP (3) JP5583022B2 (es)
KR (1) KR20100091219A (es)
CN (2) CN101932238B (es)
AR (1) AR069500A1 (es)
AU (1) AU2008329628B2 (es)
BR (1) BRPI0819690B8 (es)
CA (1) CA2706768C (es)
CL (1) CL2008003582A1 (es)
CY (1) CY1114126T1 (es)
DK (1) DK2214480T3 (es)
ES (1) ES2417179T3 (es)
HR (1) HRP20130590T1 (es)
IL (2) IL205909B (es)
MX (2) MX360827B (es)
MY (1) MY156316A (es)
NZ (1) NZ585732A (es)
PL (1) PL2214480T3 (es)
PT (1) PT2214480E (es)
RU (1) RU2498795C2 (es)
SG (1) SG10201403200RA (es)
TW (2) TWI535435B (es)
WO (1) WO2009070781A1 (es)
ZA (1) ZA201003670B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201600089A1 (ru) 2006-01-27 2017-01-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
JP5583022B2 (ja) 2007-11-30 2014-09-03 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法
US20130066075A1 (en) * 2010-05-19 2013-03-14 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis
CN102947287A (zh) * 2010-06-08 2013-02-27 M·坎杜拉 半胱胺衍生物及其在治疗非酒精性脂肪性肝炎中的用途
WO2012014218A1 (en) * 2010-07-28 2012-02-02 Orchid Research Laboratories Ltd. Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
WO2014045293A1 (en) * 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
US20130085075A1 (en) * 2011-06-06 2013-04-04 Meso Scale Technologies, Llc Diagnostic methods for liver disorders
JP6185473B2 (ja) * 2011-09-16 2017-08-23 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
MX2014004469A (es) * 2011-11-22 2014-08-01 Univ California Metodos y composiciones para tratar inflamacion y lesion isquemica.
WO2013149148A2 (en) * 2012-03-29 2013-10-03 Halo Therapeutics, Llc Dosage forms of halofuginone and methods of use
CA2875979C (en) 2012-06-06 2021-01-26 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
JP6490097B2 (ja) * 2014-04-18 2019-03-27 エルジー・ケム・リミテッド 脂肪肝疾患の予防又は治療用組成物
WO2016140237A1 (ja) * 2015-03-03 2016-09-09 興人ライフサイエンス株式会社 非アルコール性脂肪肝改善又は予防組成物
CA2991099A1 (en) * 2015-07-02 2017-01-05 Horizon Orphan Llc Ado-resistant cysteamine analogs and uses thereof
RU2595815C1 (ru) * 2015-07-13 2016-08-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
WO2017087532A1 (en) * 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
US11173135B2 (en) 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US11357768B2 (en) * 2017-06-08 2022-06-14 N-Gene Research Laboratories, Inc. Methods for treating NASH and for preventing NASH-induced HCC
WO2019046659A1 (en) * 2017-08-30 2019-03-07 First Fruits Business Ministry, Llc COMPOSITION AND METHOD FOR INCREASING SERIAL ADIPONECTIN AND REDUCING THE LIPID RESERVES OF THE ORGANISM
ES3024932T3 (en) * 2017-09-20 2025-06-05 Thiogenesis Therapeutics Inc Compounds for the treatment of cysteamine sensitive disorders
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN111544426A (zh) * 2019-02-12 2020-08-18 复旦大学 炔丙基半胱氨酸及其在制备新靶点药物中的用途
WO2020198529A1 (en) 2019-03-26 2020-10-01 The Regents Of The University Ofcalifornia Substituted amino-thiol and amino-disulfide compounds, and uses thereof
AU2020316017A1 (en) * 2019-07-19 2022-02-17 Filtricine, Inc. Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses
CN111505099B (zh) * 2020-04-21 2023-07-04 上海市普陀区中心医院 Nash的诊断标志物及其应用
CN116546981A (zh) * 2020-12-18 2023-08-04 雀巢产品有限公司 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法
CN118489805A (zh) * 2024-05-31 2024-08-16 杭州康德权饲料有限公司 半胱胺或其盐在制备预防和改善蛋鸡脂肪肝的饲料添加剂中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110441A (en) * 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JPH11302178A (ja) * 1998-02-17 1999-11-02 Otsuka Pharmaceut Factory Inc 脂肪肝予防及び治療剤
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20030137125A1 (en) * 2000-02-14 2003-07-24 Len Booysen Stabilizer unit
CN1144585C (zh) 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
CA2466869C (en) 2001-11-29 2010-01-19 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DK1471902T3 (da) 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
JP2004026716A (ja) 2002-06-25 2004-01-29 Ajinomoto Co Inc ＴＮＦα産生の抑制剤
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
CN100391448C (zh) 2003-11-19 2008-06-04 奥加生物药业(I.P.1)有限公司 提高乙醇代谢和减轻宿醉效应的物质和方法
JP4845740B2 (ja) 2003-12-19 2011-12-28 オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド 糖尿病を治療するための組成物および方法
WO2005092914A1 (en) * 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
MXPA06012752A (es) 2004-05-03 2007-02-14 Omega Bio Pharma Ip3 Ltd Cisteaminas para tratar complicaciones de hipercolesterolemia y diabetes.
MX2007008196A (es) 2005-01-05 2008-02-22 Magd Ahmed Kotb Abdalla Sintesis, produccion y utilidad de taurina como una medicina.
CA2605631A1 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
EA201600089A1 (ru) 2006-01-27 2017-01-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
WO2007121545A1 (en) 2006-04-20 2007-11-01 Universidade Estadual De Campinas-Unicamp S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
US20090304704A1 (en) 2006-05-03 2009-12-10 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
JPWO2008093764A1 (ja) 2007-02-02 2010-05-20 株式会社カネカ 糖尿病予防または治療用組成物
JP5583022B2 (ja) * 2007-11-30 2014-09-03 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法

Also Published As

Publication number Publication date
JP5583022B2 (ja) 2014-09-03
JP6121951B2 (ja) 2017-04-26
US7994226B2 (en) 2011-08-09
EP2636404B1 (en) 2019-03-20
EP2214480B1 (en) 2013-03-27
CY1114126T1 (el) 2016-07-27
CN104825430A (zh) 2015-08-12
CN104825430B (zh) 2018-05-04
EP2636404A3 (en) 2013-10-16
TWI535435B (zh) 2016-06-01
CA2706768A1 (en) 2009-06-04
US20120015005A1 (en) 2012-01-19
US20130183351A1 (en) 2013-07-18
IL205909A0 (en) 2010-11-30
US9511038B2 (en) 2016-12-06
MX360827B (es) 2018-11-16
US8263662B2 (en) 2012-09-11
TW201513855A (zh) 2015-04-16
PT2214480E (pt) 2013-07-23
KR20100091219A (ko) 2010-08-18
DK2214480T3 (da) 2013-07-08
US20160143865A1 (en) 2016-05-26
US20170304233A1 (en) 2017-10-26
MY156316A (en) 2016-02-11
CN101932238B (zh) 2015-04-08
CA2706768C (en) 2016-06-28
SG10201403200RA (en) 2014-10-30
HRP20130590T1 (en) 2013-08-31
AU2008329628B2 (en) 2014-06-26
AR069500A1 (es) 2010-01-27
BRPI0819690A2 (pt) 2014-10-07
BRPI0819690B8 (pt) 2021-05-25
HK1141945A1 (en) 2010-11-26
JP2017165735A (ja) 2017-09-21
US10307386B2 (en) 2019-06-04
MX2010005921A (es) 2010-06-11
JP2011505375A (ja) 2011-02-24
TW200927093A (en) 2009-07-01
EP2214480A4 (en) 2010-09-29
ES2417179T3 (es) 2013-08-06
IL205909B (en) 2018-05-31
JP2014237670A (ja) 2014-12-18
US20100303870A1 (en) 2010-12-02
PL2214480T3 (pl) 2013-11-29
WO2009070781A1 (en) 2009-06-04
EP2214480A1 (en) 2010-08-11
AU2008329628A1 (en) 2009-06-04
RU2010126631A (ru) 2012-01-10
NZ585732A (en) 2012-02-24
TWI478710B (zh) 2015-04-01
EP2636404A2 (en) 2013-09-11
IL254586A0 (en) 2017-11-30
ZA201003670B (en) 2011-08-31
BRPI0819690B1 (pt) 2019-07-30
RU2498795C2 (ru) 2013-11-20
CN101932238A (zh) 2010-12-29
US9149448B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BRPI0906181A2 (pt) &#34;método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer&#34;
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
BR112014032526A2 (pt) composto, e composição farmacêutica
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol &gt; 0,75 y 1
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
MX2009002054A (es) Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
GT200800235A (es) Formulacion de medicamento liquida
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
CL2011001777A1 (es) Composicion farmaceutica que contiene aleglitazar; proceso para preparar dicha composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes tipo ii o enfermedades cardiovasculares.
BRPI1011851A2 (pt) Composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, epara tratar uma doença
AR066670A1 (es) Concentrado de esmolol
AR062248A1 (es) Composiciones y metodos para tratar artritis reumatoidea
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble